Cracking the Code: Why "Standard of Care" in Pediatric Trials Needs a Serious Upgrade
"New research reveals critical gaps in how standard treatments are reported, potentially skewing results and impacting children's health."
In the world of pediatric medicine, finding the best treatments for children is paramount. Clinical trials are the cornerstone of this process, often comparing new interventions to the current "standard of care." But what happens when that "standard of care" is a moving target, poorly defined, or inconsistently applied? New research is shedding light on this critical issue, revealing that the way "standard of care" is reported in pediatric trials has significant room for improvement.
A study published in Pediatric Research has undertaken a quantitative analysis of how interventions and "standard of care" control arms are reported in pediatric clinical trials. The findings expose a concerning lack of detail and consistency, raising questions about the reproducibility and reliability of research outcomes. This is not just an academic exercise; it has real-world implications for how we evaluate treatments and ultimately, for the health of our children.
Variations in the reported usual management, also known as “standard of care” of pediatric conditions between centers is very common. The variability in practice is not uncommon, and may be due to several factors including differences in hospital budgets, physician and patient preferences, and the adoption of new treatment guide-lines and technologies at variable rates.
Why Pediatric Trials Matter
Children are a unique population because their developmental and physiological differences from adults can affect medical treatment. The World Health Organization states that clinical trials in children are essential for developing age-specific, empirically verified therapies and for determining and improving the best available treatment. ClinicalTrials.gov records participant demographics and study-specific baseline measures, while the FDA tracks information relevant to ensuring pediatric patients have access to safe and effective medical products. Since ClinicalTrials.gov launched in February 2000, more than 360,000 research studies in the United States and over 200 countries have registered, according to an analysis of pediatric clinical studies.
The Limits of Standardization
Current approaches to pediatric trials draw on core principles developed through literature and more than 30 years of global clinical-trial expertise. Efforts to improve trial quality include training and certification for pediatric research manuscript reviewers, alongside good clinical practice and research ethics training for trialists. However, a quantitative analysis specifically examined pediatric trials published in 2014 that reported using a "standard of care" control arm, indicating that the label itself requires careful examination rather than automatic acceptance. These sources support a structured approach while also highlighting the need to assess how standards are defined, applied, and reported.
From Adult Medicine to Pediatrics
A review of milestones in pediatrics and child health reports that many important developments originated in discoveries and innovations initially focused on adult disease. The review examines selected innovations relevant to children before the Archives of Disease in Childhood was inaugurated a century ago. Contemporary pediatric training formalizes expectations through ACGME milestones and specialty resources. The ACGME Pediatrics Supplemental Guide, published September 7, 2018, includes examples such as gathering a detailed history for a 13-year-old patient with fever, vomiting, and diarrhea.
The Problem with "Standard of Care": A Lack of Clarity
The research team, led by Ashley M. Yu and colleagues, focused on pediatric clinical trials published in 2014 that included a "standard of care" control arm. They used the TIDieR (Template for Intervention Description and Replication) checklist – a 12-item tool designed to ensure complete and transparent reporting of interventions – to assess the level of detail provided for both the intervention and control arms within the same study. Following a thorough screening process, 214 pediatric trials across various therapeutic areas were included in the final analysis.
- Incomplete Information: A significant number of trials failed to provide adequate details regarding the components of the "standard of care" control arm.
- Inconsistent Application: The term "standard of care" was often used loosely, with variations in interpretation across different centers and studies.
- Limited Reproducibility: The lack of detailed reporting hinders the ability of other researchers to replicate the study findings, undermining the scientific process.
A Global Research Reset
New pediatric reporting efforts are developing SPIRIT-Children and CONSORT-Children extensions to harmonize reporting in pediatric controlled-trial protocols and reports. The World Health Organization's technical report on research priorities describes a global agenda intended to address evidence gaps informing policies, clinical guidelines, and programs for children aged 0 to 9 years. Between 2000 and 2023, only 10% of globally registered trials included children; among those trials, 9% were conducted in lower-middle-income countries and 1% in low-income countries. Reviews therefore describe the field as needing a dynamic research ecosystem tailored to children's needs.
Where Trial Design Breaks Down
A systematic review of non-inferiority and equivalence studies in pediatrics found that the clinically acceptable margin was reported in 119 studies, but only 44 of those 119 studies, or 37%, reported how the margin was determined. A separate quantitative analysis assessed whether pediatric trials reporting a "standard of care" control arm also reported features such as funding, randomization, blinding, registration, sample size, and study sites. Reviews of pediatric drug development also identify children as underserved because of their physiological needs and the practical difficulty of conducting trials. Pediatric trial networks are described as important for recruitment, resource use, and global collaboration.
Reporting Quality Varies Widely
A study of the methodological and reporting quality of pediatric clinical trials found a mean overall reporting rate of 46.4% with a standard deviation of 16.6%. Across the guidelines assessed, reporting rates ranged from 13.9% to 91.7%. This wide range indicates substantial variation in how completely pediatric trials communicate their methods and results. The figures describe reporting quality, not necessarily the underlying clinical effectiveness of the interventions studied.
Moving Forward: A Call for Greater Transparency
The study authors emphasize the need for improved reporting of intervention and "standard of care" control arms in pediatric clinical trials. By adopting standardized reporting guidelines like TIDieR, researchers can ensure that all aspects of the study are transparently documented, allowing for more accurate comparisons and informed decision-making. It's time for journals to demand more comprehensive reporting of control arms, ensuring that research findings are robust, reproducible, and ultimately, beneficial for the health of children worldwide.
A System Under Strain
Children remain underserved despite significant advances in adult drug development because their physiological needs differ and pediatric trials are difficult to conduct. A major operational challenge is enrolling participants across multiple sites and jurisdictions. The Standards for Research in Child Health expert network was assembled to identify priority areas for improving the design, conduct, and reporting of pediatric clinical trials. These constraints make pediatric trial quality a systemic issue rather than a problem limited to individual studies.
Evidence Beyond the Ideal Trial
Real-world data and the evidence derived from it have been used to improve the efficiency of pediatric clinical trials and to support their planning and execution. The FDA has long used pediatric real-world data and real-world evidence to supplement information from traditional randomized trials, although these tools are not commonly used to demonstrate effectiveness in pediatrics. A 2026 case study involving pediatric patients with GiOP reported that an adequate and well-controlled randomized trial might not be feasible and questioned whether single-arm or hybrid designs could meet regulatory requirements. Together, these sources show both the practical value and the regulatory limits of evidence collected outside conventional randomized trials.